Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0FU8R
|
|||
| Drug Name |
Anifrolumab
|
|||
| Indication | Systemic lupus erythematosus [ICD-11: 4A40.0; ICD-9: 710] | Approved | [1] | |
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interferon alpha/beta receptor 2 (IFNAR2) | Target Info | Antagonist | [1] |
| Interferon gamma receptor (IFNGR2) | Target Info | Antagonist | [1] | |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Osteoclast differentiation | ||||
| Toll-like receptor signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Natural killer cell mediated cytotoxicity | ||||
| Hepatitis C | ||||
| Hepatitis B | ||||
| Measles | ||||
| Influenza A | ||||
| Herpes simplex infection | ||||
| HIF-1 signaling pathway | ||||
| Salmonella infection | ||||
| Leishmaniasis | ||||
| Chagas disease (American trypanosomiasis) | ||||
| Toxoplasmosis | ||||
| Tuberculosis | ||||
| Inflammatory bowel disease (IBD) | ||||
| Reactome | Interferon alpha/beta signaling | |||
| Regulation of IFNA signaling | ||||
| Interferon gamma signaling | ||||
| Regulation of IFNG signaling | ||||
| WikiPathways | Toll-like receptor signaling pathway | |||
| Interferon type I signaling pathways | ||||
| Interferon alpha/beta signaling | ||||
| Regulation of toll-like receptor signaling pathway | ||||
| Osteoclast Signaling | ||||
| Type II interferon signaling (IFNG) | ||||
| Interferon gamma signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761123. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.